OncoMatch/Clinical Trials/NCT06105554
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Is NCT06105554 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Belumosudil mesylate for multiple myeloma.
Treatment: Belumosudil mesylate — Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
triple class (proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 monoclonal antibody (mAb)) refractory disease
Must have received: immunomodulatory drug
triple class (proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 monoclonal antibody (mAb)) refractory disease
Must have received: anti-CD38 monoclonal antibody
triple class (proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 monoclonal antibody (mAb)) refractory disease
Cannot have received: investigational agent with known or suspected activity against multiple myeloma
Patients who are receiving any concurrent investigational agent with known or suspected activity against multiple myeloma
Lab requirements
Blood counts
ANC ≥1,000/mm3 (no growth factor support within 1 week); WBC ≥2,000/mm3 (no growth factor support within 1 week); Hemoglobin ≥8 g/dL (no transfusion within 2 weeks); Platelets ≥50,000/mm3
Kidney function
Serum creatinine within institutional normal limits OR CrCl ≥30 mL/min (24-hour urine or CKD-EPI equation)
Liver function
Total bilirubin ≤2.5x IULN (except Gilbert's disease); AST and ALT ≤2.5x IULN
Cardiac function
No NYHA class II-IV CHF; no uncontrolled angina or hypertension; no MI in previous 6 months; no clinically significant bradycardia or grade 3/4 arrhythmia; QTc <480 ms (Fridericia)
Patients must have evidence of adequate bone marrow reserves... hepatic function... cardiac function... renal function, as defined by the following: ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify